Trials / Terminated
TerminatedNCT01095250
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AIN457 | |
| DRUG | AIN457 | |
| DRUG | AIN457 | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2010-03-30
- Last updated
- 2015-11-03
- Results posted
- 2015-11-03
Locations
36 sites across 13 countries: United States, Canada, Egypt, France, Germany, Hungary, India, Israel, Japan, Singapore, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01095250. Inclusion in this directory is not an endorsement.